- Home
- ALXO vs DMA Comparison
ALXO vs DMA Comparison
Compare ALXO & DMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALXO | DMA |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.7M | 80.8M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALXO | DMA |
|---|---|---|
| Price | $1.33 | $9.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $3.30 | N/A |
| AVG Volume (30 Days) | ★ 177.3K | 34.6K |
| Earning Date | 11-07-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 2.04% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.40 | $4.78 |
| 52 Week High | $2.27 | $8.00 |
Technical Indicators
Market Signals| Indicator | ALXO | DMA |
|---|---|---|
| Relative Strength Index (RSI) | 42.54 | 58.01 |
| Support Level | $1.37 | $8.92 |
| Resistance Level | $1.53 | $9.14 |
| Average True Range (ATR) | 0.11 | 0.14 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 12.12 | 69.77 |
Price Performance
Historical ComparisonAbout ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.